Logo image of CTSO

CYTOSORBENTS CORP (CTSO) Stock Fundamental Analysis

NASDAQ:CTSO - Nasdaq - US23283X2062 - Common Stock - Currency: USD

1.15  -0.07 (-5.74%)

Fundamental Rating

2

Overall CTSO gets a fundamental rating of 2 out of 10. We evaluated CTSO against 190 industry peers in the Health Care Equipment & Supplies industry. CTSO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, CTSO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CTSO has reported negative net income.
CTSO had a negative operating cash flow in the past year.
CTSO had negative earnings in each of the past 5 years.
In the past 5 years CTSO always reported negative operating cash flow.
CTSO Yearly Net Income VS EBIT VS OCF VS FCFCTSO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -39.06%, CTSO is doing worse than 61.17% of the companies in the same industry.
CTSO's Return On Equity of -143.63% is on the low side compared to the rest of the industry. CTSO is outperformed by 72.34% of its industry peers.
Industry RankSector Rank
ROA -39.06%
ROE -143.63%
ROIC N/A
ROA(3y)-44.28%
ROA(5y)-42.39%
ROE(3y)-84.83%
ROE(5y)-165.57%
ROIC(3y)N/A
ROIC(5y)N/A
CTSO Yearly ROA, ROE, ROICCTSO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800

1.3 Margins

Looking at the Gross Margin, with a value of 62.71%, CTSO is in the better half of the industry, outperforming 63.83% of the companies in the same industry.
In the last couple of years the Gross Margin of CTSO has declined.
CTSO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.52%
GM growth 5Y-1.58%
CTSO Yearly Profit, Operating, Gross MarginsCTSO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150

More info and screens

1

2. Health

2.1 Basic Checks

CTSO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CTSO has been increased compared to 1 year ago.
CTSO has more shares outstanding than it did 5 years ago.
CTSO has a worse debt/assets ratio than last year.
CTSO Yearly Shares OutstandingCTSO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
CTSO Yearly Total Debt VS Total AssetsCTSO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -8.04, we must say that CTSO is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.04, CTSO is doing worse than 76.60% of the companies in the same industry.
A Debt/Equity ratio of 1.06 is on the high side and indicates that CTSO has dependencies on debt financing.
With a Debt to Equity ratio value of 1.06, CTSO is not doing good in the industry: 79.26% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF N/A
Altman-Z -8.04
ROIC/WACCN/A
WACC9%
CTSO Yearly LT Debt VS Equity VS FCFCTSO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 1.97 indicates that CTSO should not have too much problems paying its short term obligations.
With a Current ratio value of 1.97, CTSO is not doing good in the industry: 66.49% of the companies in the same industry are doing better.
A Quick Ratio of 1.58 indicates that CTSO should not have too much problems paying its short term obligations.
CTSO has a Quick ratio (1.58) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.97
Quick Ratio 1.58
CTSO Yearly Current Assets VS Current LiabilitesCTSO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

CTSO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.48%, which is quite impressive.
CTSO shows a small growth in Revenue. In the last year, the Revenue has grown by 1.81%.
The Revenue has been growing by 10.07% on average over the past years. This is quite good.
EPS 1Y (TTM)31.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80.95%
Revenue 1Y (TTM)1.81%
Revenue growth 3Y-3.93%
Revenue growth 5Y10.07%
Sales Q2Q%6.58%

3.2 Future

Based on estimates for the next years, CTSO will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.26% on average per year.
CTSO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.17% yearly.
EPS Next Y53.45%
EPS Next 2Y29.65%
EPS Next 3Y23.07%
EPS Next 5Y15.26%
Revenue Next Year5.35%
Revenue Next 2Y8.45%
Revenue Next 3Y12.72%
Revenue Next 5Y27.17%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CTSO Yearly Revenue VS EstimatesCTSO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
CTSO Yearly EPS VS EstimatesCTSO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CTSO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CTSO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTSO Price Earnings VS Forward Price EarningsCTSO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTSO Per share dataCTSO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as CTSO's earnings are expected to grow with 23.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.65%
EPS Next 3Y23.07%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CTSO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYTOSORBENTS CORP

NASDAQ:CTSO (2/20/2025, 8:08:57 PM)

1.15

-0.07 (-5.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-06 2025-03-06/amc
Inst Owners34.64%
Inst Owner Change-7.23%
Ins Owners3.29%
Ins Owner Change3.72%
Market Cap63.05M
Analysts80
Price Target7.14 (520.87%)
Short Float %3.9%
Short Ratio6.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.82%
Min EPS beat(2)19.56%
Max EPS beat(2)38.08%
EPS beat(4)4
Avg EPS beat(4)16.73%
Min EPS beat(4)1.96%
Max EPS beat(4)38.08%
EPS beat(8)5
Avg EPS beat(8)6.56%
EPS beat(12)5
Avg EPS beat(12)-18.48%
EPS beat(16)6
Avg EPS beat(16)-32.02%
Revenue beat(2)1
Avg Revenue beat(2)-4.67%
Min Revenue beat(2)-9.58%
Max Revenue beat(2)0.24%
Revenue beat(4)1
Avg Revenue beat(4)-4.94%
Min Revenue beat(4)-9.58%
Max Revenue beat(4)0.24%
Revenue beat(8)3
Avg Revenue beat(8)-3.91%
Revenue beat(12)4
Avg Revenue beat(12)-5.3%
Revenue beat(16)5
Avg Revenue beat(16)-5.2%
PT rev (1m)40%
PT rev (3m)40%
EPS NQ rev (1m)5.01%
EPS NQ rev (3m)-18.75%
EPS NY rev (1m)1.11%
EPS NY rev (3m)4.3%
Revenue NQ rev (1m)2.71%
Revenue NQ rev (3m)-1.94%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.67
P/FCF N/A
P/OCF N/A
P/B 4.85
P/tB 4.85
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0.69
BVpS0.24
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.06%
ROE -143.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.71%
FCFM N/A
ROA(3y)-44.28%
ROA(5y)-42.39%
ROE(3y)-84.83%
ROE(5y)-165.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.52%
GM growth 5Y-1.58%
F-Score5
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.83%
Cap/Sales 1.81%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.97
Quick Ratio 1.58
Altman-Z -8.04
F-Score5
WACC9%
ROIC/WACCN/A
Cap/Depr(3y)461.47%
Cap/Depr(5y)380.21%
Cap/Sales(3y)10.37%
Cap/Sales(5y)8.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80.95%
EPS Next Y53.45%
EPS Next 2Y29.65%
EPS Next 3Y23.07%
EPS Next 5Y15.26%
Revenue 1Y (TTM)1.81%
Revenue growth 3Y-3.93%
Revenue growth 5Y10.07%
Sales Q2Q%6.58%
Revenue Next Year5.35%
Revenue Next 2Y8.45%
Revenue Next 3Y12.72%
Revenue Next 5Y27.17%
EBIT growth 1Y22.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.76%
EBIT Next 3Y28.62%
EBIT Next 5YN/A
FCF growth 1Y47.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.87%
OCF growth 3YN/A
OCF growth 5YN/A